Copyright
©The Author(s) 2021.
World J Clin Oncol. Sep 24, 2021; 12(9): 746-766
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.746
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.746
Table 1 Clinical studies applying various hematopoietic stem cell mobilization chemotherapy + granulocyte colony-stimulating factor protocols in patients with relapsed/refractory germ cell tumors
Ref. | Number of patients | Successful mobilization | Mobilization regimen |
Fruehauf et al[149] 1995 (prospective analysis) | 15 | Median BM 31.49 × 106/kg PB 0.46 × 106/kg 100% | Cisplatin 100 mg/m2 etoposide 75 mg/m2 ifosfamide 2 g/m2 + G-CSF |
Tada et al[150] 1999 (retrospective analysis) | 6 | 2.5 × 108/kg 100% | Cisplatin 200 mg/m2 ifosfamide 4 g/m2 etoposide 100 mg/m2 d1-d3 + G-CSF |
Rodenhuis et al[151] 1999 (multicenter prospective phase II) | 35 | 10.3 × 106/kg 100% | Cisplatin 200 mg/m2 ifosfamide 4 g/m2 etoposide 100 mg/m2 d1-d3 + G-CSF |
Lotz et al[152] 2005 TAXIF 2005 (retrospective analysis) | 45 | 9 × 106/kg (for 3 HDCT) 100% | Epirubicin 120 mg/m2 - paclitaxel 200 mg/m2 + G-CSF |
Argawal et al[102] 2009 (retrospective analysis) | 37 | 3-6 × 106/kg 100% | ifosfamide 2-4.5 g/m2 + G-CSF |
Feldman et al[153] 2010 (prospective phase I/II) | 107 | > 2 × 106/kg 100% | TI: paclitaxel 200 mg/m2 d1 ifosfamide 2 g/m2 d1-d3 + G-CSF |
Haugnes et al[154] 2012 (prospective analysis) | 882 | > 2 × 106/kg 100% | BEP-ifosfamide + G-CSF |
Mohr et al[155] 2012 (retrospective analysis) | 44 | > 4 × 106/kg 100% | PEI (cisplatin, etoposide, ifosfamide) + G-CSF Plerixafor in poor mobilizers |
Necchi et al[156] 2015 (review) | 42 | > 2 × 106/kg 100% | BEP + G-CSF |
Moeung et al[157] 2017 (pharmacokinetic phase II study) | 89 | > 9 × 106/kg (for 3 HDCT) (1-2 cycles) 100% | TI: paclitaxel, ifosfamide + G-CSF |
Hamid et al[106] 2018 (retrospective analysis) | 35 | 10/35 plerixafor + G-CSF 95% | TI: paclitaxel, ifosfamide or TIP |
Argawal et al[158] 2019 (retrospective analysis) | 321 | 172 allogeneic 95% 149 autologous 73% 77/149 without plerixafor → 64% success 72/149 with plerixafor → 82% success | G-CSF ± Plerixafor |
Yildiz et al[159] 2020 (retrospective analysis) | 50 | > 2 × 106/kg 100% | TIP + G-CSF |
Ussowicz et al[160] 2020 (retrospective analysis) | 18 (children) | Median: 4.56 × 106/kg 100% | Cyclophosphamide 4 g/m2 + G-CSF |
Chevreau et al[161] 2020 (multicenter prospective phase II) | 89 | > 9 × 106/kg (for 3 HDCT) 100% | TI: paclitaxel, ifosfamide + G-CSF |
Table 2 Clinical studies applying plerixafor with granulocyte colony-stimulating factor ± chemotherapy for hematopoietic stem cells mobilization in patients with relapsed/refractory germ cell tumors
Ref. | Number of patients participating | Successful mobilization rates on previously failed chemotherapy + G-SCF driven mobilization (> 2 × 106) | Mobilization techniques |
Kobold et al[128] 2011 (Retrospective analysis) | 6 | 66.67% (4) | Chemo + G-CSF failed |
Plerixafor + G-CSF | |||
Horwitz et al[162] 2012 (Retrospective analysis) | 21 | 76% (17) | Chemo + G-CSF failed |
Plerixafor + G-CSF | |||
Worel et al[163] 2012 (Retrospective analysis) | 11 | 91% (10) | Plerixafor + G-CSF |
Garcia-Escobar et al[164] 2014 (Case series) | 5 | 80% (4) | Chemo + G-CSF failed |
Plerixafor + G-CSF | |||
Kosmas et al[165] 2014 (Pilot study) | 14 (3) | 100% (3) | Chemo + G-CSF failed |
Chemo + Plerixafor + G-CSF | |||
O’Hara et al[166] 2014 (Retrospective analysis) | 9 (3) | 100% (3) | Plerixafor + G-CSF |
- Citation: Porfyriou E, Letsa S, Kosmas C. Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors. World J Clin Oncol 2021; 12(9): 746-766
- URL: https://www.wjgnet.com/2218-4333/full/v12/i9/746.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i9.746